MA32355B1 - Association de la dronedarone avec au moins un diuretique, son application en therapeutique - Google Patents

Association de la dronedarone avec au moins un diuretique, son application en therapeutique

Info

Publication number
MA32355B1
MA32355B1 MA33318A MA33318A MA32355B1 MA 32355 B1 MA32355 B1 MA 32355B1 MA 33318 A MA33318 A MA 33318A MA 33318 A MA33318 A MA 33318A MA 32355 B1 MA32355 B1 MA 32355B1
Authority
MA
Morocco
Prior art keywords
diuretic
dronidarone
apply
connect
treatment
Prior art date
Application number
MA33318A
Other languages
Arabic (ar)
English (en)
Inventor
Davide Radzik
Eickels Martin Van
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39684441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32355(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32355B1 publication Critical patent/MA32355B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Association de dronedarone ou un de ses sels pharmaceutiquement acceptables avec au moins un diurétique, son application en thérapeutique.
MA33318A 2008-04-17 2010-11-03 Association de la dronedarone avec au moins un diuretique, son application en therapeutique MA32355B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0802128A FR2930149B1 (fr) 2008-04-17 2008-04-17 Association de dronedarone avec au moins un diuretique, son application en therapeutique
US4599908P 2008-04-18 2008-04-18
PCT/FR2009/000450 WO2009133310A2 (fr) 2008-04-17 2009-04-16 Association de la dronedarone avec au moins un diuretique, son application en therapeutique

Publications (1)

Publication Number Publication Date
MA32355B1 true MA32355B1 (fr) 2011-06-01

Family

ID=39684441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33318A MA32355B1 (fr) 2008-04-17 2010-11-03 Association de la dronedarone avec au moins un diuretique, son application en therapeutique

Country Status (26)

Country Link
US (1) US20110136899A1 (fr)
EP (1) EP2280700A2 (fr)
JP (1) JP2011517694A (fr)
KR (1) KR20110005245A (fr)
CN (1) CN102065856A (fr)
AR (1) AR071326A1 (fr)
AU (1) AU2009241966A1 (fr)
BR (1) BRPI0910559A2 (fr)
CA (1) CA2721560A1 (fr)
CL (1) CL2009000918A1 (fr)
CO (1) CO6300842A2 (fr)
CR (1) CR11735A (fr)
DO (1) DOP2010000308A (fr)
EA (1) EA201071203A1 (fr)
EC (1) ECSP10010552A (fr)
FR (1) FR2930149B1 (fr)
IL (1) IL208749A0 (fr)
MA (1) MA32355B1 (fr)
MX (1) MX2010011401A (fr)
NI (1) NI201000171A (fr)
PE (1) PE20091808A1 (fr)
SV (1) SV2010003702A (fr)
TW (1) TW200951117A (fr)
UY (1) UY31772A (fr)
WO (1) WO2009133310A2 (fr)
ZA (1) ZA201007390B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684564A1 (fr) * 2008-04-17 2014-01-15 Sanofi Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l' hospitalisation ou prévenir la fibrillation auriculaire
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4868179A (en) * 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
US4988513A (en) * 1990-01-09 1991-01-29 Monsanto Company Method of treating hypokalemia
FR2665444B1 (fr) * 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6897305B2 (en) * 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
FR2803846B1 (fr) * 2000-01-17 2002-04-05 Clariant France Sa 3-(1-hydroxy-pentylidene)-5-nitro-3h-benzofuran-2-one, son procede de preparation et son utilisation
FR2817864B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Derive de methanesulfonamido-benzofurane, son procede de preparation et son utilisation comme intermediaire de synthese
FR2817750B1 (fr) * 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
FR2817865B1 (fr) * 2000-12-11 2005-02-18 Sanofi Synthelabo Derive aminoalkoxybenzoyle sous forme de sel, son procede de preparation et son utilisation comme intermediaire de synthese
CA2433861A1 (fr) * 2000-12-27 2002-07-04 Genzyme Corporation Liberation controlee d'agents anti-arythmiques
US6831102B2 (en) * 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
US20030229007A1 (en) * 2002-05-30 2003-12-11 Roberto Levi Form of human renin and its use as a target in treatments for cardiac ischemia and arrhythmia
DE10237819A1 (de) * 2002-08-19 2004-03-04 Bayer Ag 5-Nitrobenzofurane
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20060093673A1 (en) * 2003-06-27 2006-05-04 Coury Arthur J Controlled release of anti-arrhythmic agents
WO2005018635A2 (fr) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Activite i modulant des canaux ioniques
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7820702B2 (en) * 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7772232B2 (en) * 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US20070248564A1 (en) * 2006-04-25 2007-10-25 Roxane Laboratories, Inc. Formulation of sodium polystyrene sulfonate suspension for the treatment of hyperkalemia
US20090076137A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched dronedarone
EP2684564A1 (fr) * 2008-04-17 2014-01-15 Sanofi Utilisation de dronédarone dans un médicament utilisé pour prévenir un épisode cardiovasculaire menant à l' hospitalisation ou prévenir la fibrillation auriculaire
FR2930150B1 (fr) * 2008-06-24 2011-01-14 Sanofi Aventis Utilisation de la dronedarone pour la preparation d'un medicament destine a reguler le taux de potassium dans le sang
EP2116239A1 (fr) * 2008-04-29 2009-11-11 Sanofi-Aventis Procédé pour la gestion des risques associés à une augmentation de la créatinine sérique pendant un traitement à la dronédarone
EP2133074A1 (fr) * 2008-06-10 2009-12-16 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la fibrillation auriculaire permanente
EP2133075A1 (fr) * 2008-06-10 2009-12-16 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention de la cardioversion
EP2153830A1 (fr) * 2008-08-07 2010-02-17 Sanofi-Aventis Utilisation de dronédarone pour la préparation d'un médicament destiné à la prévention des accidents vasculaires cérébraux ou des accidents ischémiques transitoires
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) * 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation

Also Published As

Publication number Publication date
EA201071203A1 (ru) 2011-06-30
WO2009133310A3 (fr) 2009-12-23
ZA201007390B (en) 2012-01-25
FR2930149B1 (fr) 2011-02-18
ECSP10010552A (es) 2010-11-30
JP2011517694A (ja) 2011-06-16
SV2010003702A (es) 2011-03-04
KR20110005245A (ko) 2011-01-17
EP2280700A2 (fr) 2011-02-09
PE20091808A1 (es) 2009-12-03
CA2721560A1 (fr) 2009-11-05
CO6300842A2 (es) 2011-07-21
CN102065856A (zh) 2011-05-18
WO2009133310A2 (fr) 2009-11-05
TW200951117A (en) 2009-12-16
CL2009000918A1 (es) 2010-06-11
US20110136899A1 (en) 2011-06-09
CR11735A (es) 2010-11-22
NI201000171A (es) 2012-01-23
MX2010011401A (es) 2011-03-02
AU2009241966A1 (en) 2009-11-05
BRPI0910559A2 (pt) 2015-09-22
DOP2010000308A (es) 2010-11-30
UY31772A (es) 2009-12-14
AR071326A1 (es) 2010-06-09
FR2930149A1 (fr) 2009-10-23
IL208749A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
LT3205334T (lt) Būdas ir kompozicija, skirti akių hipertenzijai ir glaukomai gydyti
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
TW200833684A (en) 5,6-ring annulated indole derivatives and methods of use thereof
WO2009026657A8 (fr) Agonistes flavonoïdes de ppar
EP2294184A4 (fr) Traitement de maladies oculaires et d une néovascularisation excessive utilisant un traitement combiné
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TW200738263A (en) ANG2 and VEGF inhibitor combinations
EA201490268A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор
WO2007103540A3 (fr) Polytherapie presentant des inhibiteurs cox non selectifs en vue de prevenir des lesions gastriques liees a cox
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
NO20072890L (no) Behandling av mastitt
MX342832B (es) Tratamiento o prevencion de una infeccion.
MA32355B1 (fr) Association de la dronedarone avec au moins un diuretique, son application en therapeutique
DK2124640T3 (da) Glucoseisomerase til anvendelse i behandlingen af fruktoseintolerans
WO2007047608A3 (fr) Substances therapeutiques ciblees sur la fibrine
WO2010042530A3 (fr) Nlrc5 en tant que cible pour un traitement immunitaire
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
WO2008115478A3 (fr) Procédé de détection et de traitement du cancer
TW200738267A (en) Methods of increasing lymphatic function
WO2010127096A3 (fr) Nouveaux traitements thérapeutiques utilisant la centhaquine
WO2011019423A3 (fr) Modulation de récepteurs pilr pour traiter les infections microbiennes